Latest News for: phase iii trial

Edit

Newron presents 2024 financial results and provides 2025 outlook

Pharmiweb 01 Apr 2025
Under the terms of the agreement, Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron’s upcoming Phase III trial and cover the costs related to this population.
Edit

Pfizer opens research and development centre in Beijing

Urdu Point 01 Apr 2025
<p>BEIJING, (UrduPoint / Pakistan Point News / WAM - 01st Apr, 2025) US pharmaceutical giant Pfizer's new research and development (R&amp;D) centre officially opened at BioPark in the ...
Edit

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Pharmiweb 31 Mar 2025
The PROCEED trial is expected to be completed in the first half of 2026 with planned pivotal phase III initiation in second half of 2026 ... Lundbeck initiated the PROCEED Phase IIb trial March 2024.
Edit

Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight ...

GetNews 31 Mar 2025
The Phase III study (NCT05246280), which included 523 participants, aimed to validate the effectiveness of ... Late-stage products (Phase III) ... Rheumatoid Arthritis Late Stage Products (Phase II/III).
Edit

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Pharmiweb 31 Mar 2025
Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs ... NIAGARA is the largest global Phase III trial in this setting.&nbsp;.
Edit

US pharmaceutical giant opens R&D center in Beijing

China Daily 31 Mar 2025
As the company's third R&D center in China, the new facility aims to enhance its existing drug development network in the country, integrating China into Pfizer's global early-stage clinical trials and all pivotal phase III studies ...
×